Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker Corporation reported Q4 2022 revenues of $708.4 million, up 3.6% year-over-year, with 8.9% organic growth. GAAP EPS was $0.66, while non-GAAP EPS rose 25.4% to $0.74. For FY 2022, revenues reached $2.531 billion, marking an increase of 4.7%, and 10.2% organic growth. GAAP EPS for FY 2022 was $1.99 with a non-GAAP EPS of $2.34, up 11.4%. Looking ahead, Bruker projects FY 2023 revenues of $2.81 to $2.86 billion with non-GAAP EPS guidance of $2.52 to $2.57, indicating 8% to 10% growth.
Bruker Corporation has successfully installed two novel, compact 1.0 GHz NMR systems for structural and molecular biology applications at RIKEN in Japan and the University of Barcelona in Spain, ahead of schedule in late 2022. These Ascend Evo 1.0 GHz NMR systems operate at 4.2 Kelvin and consume approximately 65% less liquid helium compared to previous models. The compact design eases site installation and is expected to enhance research in biomolecular dynamics. The installations are already generating valuable scientific data, contributing to advancements in life sciences and clinical research.
Bruker Corporation (Nasdaq: BRKR) will report its fourth quarter and fiscal year 2022 financial results before market opening on February 9, 2023. A conference call and webcast will follow at 8:30 a.m. EST to discuss these results and current business trends. Investors can listen to the webcast at Bruker's Investor Relations website. Pre-registration for the call is available to streamline access. A replay of the conference call will be accessible from March 9, 2023, along with a slide presentation available shortly before the webcast begins.
Bruker Corporation (Nasdaq: BRKR) announced its acquisition of ACQUIFER Imaging GmbH, enhancing its bioimaging solutions. This acquisition includes ACQUIFER's HIVE data management system, which supports high-performance computing and big-data storage for microscopy applications. Additionally, the IM04 Imaging Instrument expands Bruker's portfolio into high-content screening. The financial details of the deal were not disclosed, but it is expected to enhance Bruker's capabilities in life science research, particularly in organoid and stem cell studies.
Bruker has announced a strategic partnership with Biognosys, acquiring a majority stake to enhance access to Biognosys' CRO services and Spectronaut® software for proteomics research. The partnership aims to support drug discovery, biomarker development, and clinical trials, with plans to establish a new advanced proteomics facility in the US. The collaboration leverages Bruker's technology alongside Biognosys' expertise, promising improved proteomics capabilities and expanded services for their biomarker and biopharma clientele.
Bruker Corporation (Nasdaq: BRKR) will present at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, at 10:30 AM EST in San Francisco. Key executives, including Chairman Frank Laukien and CFO Gerald Herman, will represent the company. A live audio webcast of the presentation can be accessed via the Investor Relations section of Bruker's website, with a replay available for 30 days thereafter. Bruker specializes in high-performance scientific instruments that support significant advancements in life sciences and material sciences.
Bruker Corporation (Nasdaq: BRKR) announced significant multi-year contracts valued at approximately $50 million with its majority-owned RI Research Instruments GmbH and Bruker Energy & Supercon Technologies (BEST). These contracts involve supplying key technology components for major fusion projects in Europe and Asia. The projects include providing Inner Vertical Targets for the ITER fusion initiative and high-current density RRP® superconductors for a tokamak project. This advancement positions Bruker to play a vital role in future sustainable energy solutions.
Kiyatec Inc. has successfully closed its Series C funding round, raising US$18 million led by new investor Bruker (BRKR) and supported by LabCorp (LH) and others. The funds will enhance the adoption of Kiyatec's clinical testing and preclinical pharma services, vital for improving cancer treatment outcomes. Kiyatec's 3D-Predict™ Glioma test has shown significant clinical correlations, allowing better therapy selection for glioblastoma patients. The company aims to grow its revenue through innovative testing and drug development partnerships.
Bruker Corporation (Nasdaq: BRKR) has signed a definitive agreement to acquire Neurescence Inc., known for its innovative Multiscopes™ technology that allows simultaneous multi-region optical neuroimaging. Neurescence's Chromatone™ system, which minimizes weight on animals, enhances the investigation of neuron functions. This acquisition strengthens Bruker's portfolio in animal imaging and expands its capabilities in neuroresearch. Financial terms of the deal were not disclosed, but the acquisition is expected to leverage synergies with Bruker's existing products, positioning the company as a leader in this field.
Bruker Corporation (NASDAQ: BRKR) has announced a quarterly cash dividend of $0.05 per share, which will be paid on December 16, 2022. The record date for shareholders is December 1, 2022. This decision reflects Bruker’s commitment to returning value to its investors while continuing to manage risks and uncertainties outlined in its SEC filings. The company specializes in high-performance scientific instruments and solutions aimed at improving life science and diagnostics.